Journal Article Ppublish 1 citation
PubMed: 37867976 DOI: 10.4103/ijem.ijem_78_23
Prevention of Type 1 Diabetes: Current Perspective.
Indian J Endocrinol Metab 27(4):277-285
Authors: Arun K Pande, Deep Dutta, Rajiv Singla
Affiliations
- Consultant Endocrinologist, Lucknow Endocrine Diabetes and Thyroid Clinic, Lucknow, Uttar Pradesh, India.
- Consultant Endocrinologist, CEDAR Superspeciality Healthcare, Dwarka, New Delhi, India.
- Consultant Endocrinologist, Kalpavriksh Healthcare, Dwarka, Delhi, India.
Abstract
People living with type 1 Diabetes (T1D) and their families have poor perception of health related quality of life. Therapies for T1D are becoming better with time, but they still involve a lot of effort. Prevention of T1D, if successful, has potential to change lives of millions of families across the globe. Type 1 diabetes is an autoimmune disease with underlying genetic predisposition for autoimmunity against beta cell antigens upon exposure to an environmental trigger. Identifying underlying primary antigen responsible for initiating autoimmune cascade, avoiding environmental trigger and modifying immunity has all been used as strategies for preventing or delaying onset of type 1 diabetes. Primary prevention for type 1 diabetes is hindered by difficulty in identifying at-risk population and also due to lack of effective preventive strategy. Secondary prevention, in children with presence of autoimmunity, has recently received a boost with approval of Teplizumab, an immunity modifying drug by its Anti-CD3 action. Application of preventive strategies would also change based on country specific incidence, prevalence and availability of health resources. In current review, an update on preventive strategies for type 1 diabetes is being discussed as well as their applicability in Indian context.
MeSH
Immunity, Autoimmunity, Quality Of Life, Diabetes Mellitus, Type 1